Form 8-K - Current report:
SEC Accession No. 0001683168-20-000966
Filing Date
2020-03-26
Accepted
2020-03-26 16:30:11
Documents
2
Period of Report
2020-03-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm 8-K 20666
2 DEVELOPMENT AGREEMENT cns_8k-ex1001.htm EX-10.1 49314
  Complete submission text file 0001683168-20-000966.txt   71120
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 20746446
SIC: 2834 Pharmaceutical Preparations